Table 4.
Results of the population subgroups according to the risk factors associated
| Population subgroup A | Population subgroup B | Population subgroup C | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Non-prophylaxis | Palivizumab | Incremental palivizumab vs non-prophylaxis. | Non-prophylaxis | Palivizumab | Incremental palivizumab vs non-prophylaxis. | Non-prophylaxis | Palivizumab | Incremental palivizumab vs non-prophylaxis. | |
| Effectiveness | |||||||||
| QALYs | 5.16 | 5.25 | 0.0889 | 5.18 | 5.26 | 0.0821 | 5.18 | 5.26 | 0.0822 |
| Costs | |||||||||
| Total costs | €1,589.57 | €2,616.92 | €1,027.34 | €1,088.90 | €2,252.69 | €1,163.79 | €1,063.23 | €2,209.48 | €1,146.25 |
| Prophylaxis costs | €0.00 | €1,886.78 | €1,886.78 | €0.00 € | €1,886.78 | €1,886.78 | €0.00 | €1,886.78 | €1,886.78 |
| Hospital related costsa | €1,105.98 € | €571.02 | €-534.96 | €637.14 | €216.39 | €-420.75 | €613.10 | €174.31 | €-438.79 |
| Recurrent wheezing costs | €483.59 | €159.11 | €-324.48 | €451.76 | €149.52 € | €-302.24 | €450.13 | €148.38 | €-301.74 |
| ICUR (€/QALY gained) | 11,550.37 | 14,177.18 | 13,937.61 | ||||||
QALY: Quality adjusted life years; Subgroup A: 2 major risk factors and 2 minor risk factors; Subgroup B: 2 major factors and 1 minor factor; Subgroup C: 2 major factors; Major factors included chronological age less than10 weeks at the beginning of RSV season or being born during the first 10 weeks of the season; school-age siblings or day-care attendance whereas minor factors included mother smoking during pregnancy and male gender [33]. Major factors: chronological age less than 10 weeks at the beginning of RSV season or being born during the first 10 weeks of the season; school-age siblings or day-care attendance. Minor factors: mother smoking during pregnancy and male gender
aHospital related costs included emergency visit prior hospitalization cost, hospital and ICU admission costs